SOUL: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes omslagafbeelding

SOUL: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

SOUL: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Nu gratis luisteren, zonder abonnement

Details bekijken

De grootste deal van het seizoen | 3 maanden voor maar € 0,99 per maand + € 15 Audible-tegoed

Daarna € 6,99 per maand – voorwaarden zijn van toepassing. Maandelijks opzegbaar.
Over deze titel

SOUL is a large randomized trial of oral semaglutide in adults with type 2 diabetes and established cardiovascular or kidney disease. In this Hormone Insight clinical evidence discussion, we cover the five-part PICO, the primary MACE result, absolute event rates, the non-significant kidney secondary outcome, patient selection, and limits of generalization. Fahad narration, clean voice-only production, no music. Primary source: PMID 40162642. DOI 10.1056/NEJMoa2501006. For healthcare professionals. This episode is an evidence discussion, not a substitute for the original paper, product information, local guidance, or individualized clinical judgment.

adbl_web_anon_alc_button_suppression_t1
Nog geen reviews beschikbaar